Femasys Inc is a healthcare company focused on developing innovative products and solutions to enhance women's reproductive health. The company aims to address unmet medical needs in areas such as fertility and contraception through advanced medical technologies. Femasys is committed to improving patient outcomes by offering minimally invasive and user-friendly procedures, thereby empowering women with more options for their reproductive health management. Their research and development efforts are geared toward creating safer, effective, and cost-efficient treatments that can be accessible to a broader audience. Read More
ATLANTA, May 30, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at a public offering price of $0.85 per share and a separate concurrent private placement of 1,686,275 shares of its common stock at a price of $0.85 per share sold to certain existing institutional stockholders of Femasys and a price of $1.02 per share to certain of its directors and officers. The gross proceeds of the public offering and private placement to Femasys, before deducting the underwriting and placement agent discounts and commissions and other public offering and private placement expenses payable by Femasys, are expected to be approximately $4.5 million. Femasys intends to use the net proceeds from the public offering and the private placement for expansion of commercial efforts, development of its products and product candidates, general corporate purposes, capital expenditures, working capital and general and administrative expenses. In addition, Femasys has granted the underwriter a 30-day option to purchase up to an additional 540,000 shares of its common stock sold in the public offering. All of the securities are to be sold by the Company. The public offering and the private placement are expected to close on or about June 2, 2025, subject to satisfaction of customary closing conditions. The closing of the public offering is not contingent on the private placement, and the closing of the private placement is not contingent on the public offering.
ATLANTA, May 29, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Femasys expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. In addition, certain existing institutional stockholders of Femasys and certain of its directors and officers have indicated an interest to purchase shares of common stock in a concurrent private placement.
-- Company delivers on mission to transform women’s health with innovative solutions, including FemaSeed® for first-line infertility treatment and FemBloc® non-surgical permanent birth control (full system approval pending in Europe) --
-- Company expands commercial product offering with FemBloc® permanent birth control (delivery system) approval in Europe and signed partnerships for distribution in Spain --
NEW YORK, NY / ACCESS Newswire / March 18, 2025 / The Investor Summit is excited to announce that presentations from Q1 Investor Summit are now available for on-demand viewing. Attendees and investors who missed the live sessions can now access company presentations at their convenience.
-- Company taps first EU distributors, Comercial Medico Quirurigca, SA and Durgalab, as the first globally to be granted rights to commercialize FemBloc® --
--Positive data from prospective, multi-center trials confirmed compelling effectiveness and five-year safety with high satisfaction from both patients and practitioners--
European patents expand coverage for both essential components of FemBloc for fallopian tube occlusion, resulting in non-surgical permanent contraception
